secwatch.observer — SEC 8-K summary
======================================

Issuer:     MPLX LP (MPLX)
CIK:        0001552000
Form:       8-K
Filed at:   2022-10-11T23:59:59+00:00
Accession:  0001552000-22-000040
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MPLX CEO Hennigan reports no sign of cancer after treatment
-----------------------------------------------------------

- CEO Michael Hennigan says tests show no sign of throat cancer following treatment.
- Completed seven-week radiation and chemotherapy protocol a few months ago.
- Prognosis is excellent; he will continue to be monitored as a routine precaution.
- Hennigan remains Chairman, President and CEO and is focused on leading MPLX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1552000/000155200022000040/0001552000-22-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1552000/000155200022000040/mplx-20221011.htm
  HTML page:      https://secwatch.observer/filing/0001552000-22-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer